Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock Price & News

BIO:NYSE

Bio-Rad Laboratories, Inc. Class A Common Stock

$366.36

-1.11%

(-4.11) 1D

$366.36

0.00% (0.00)

After hours

Closed: Nov 13, 4:00:03 PM GMT-5 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for BIO...

Open

$370.19

High

$373.50

Low

$364.11

Mkt. cap

9.95B

Avg. vol.

243.52K

Volume

256.21K

P/E ratio

9.65

52-wk high

$396.23

52-wk low

$236.73

EPS

$37.97

Beta

1.06

Shares outstanding

21.83M

No. of employees

Open

$370.19

High

$373.50

Low

$364.11

Mkt. cap

9.95B

Avg. vol.

243.52K

Volume

256.21K

P/E ratio

9.65

52-wk high

$396.23

52-wk low

$236.73

EPS

$37.97

Beta

1.06

Shares outstanding

21.83M

No. of employees

Related stocks

CRL

Charles River Laboratories Intrtnl, Inc.

$337.97

-0.87%

TMO

Thermo Fisher Scientific Inc

News stories

From web sources and news partners

Yahoo Finance

1 day ago

Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds

Nasdaq

1 day ago

Chartstopper: November 13, 2026

24/7 Wall St.

1 hour ago

He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076

CNBC

2 days ago

Nasdaq Composite slides as Nvidia shares tumble on Jensen Huang’s exit; oil prices jump

Profile

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide. Wikipedia

About Bio-Rad Laboratories, Inc. Class A Common Stock

CEONorman David Schwartz

Employees7.45K

Founded1952

HeadquartersHercules, California, United States

SectorHealth Care

Industry-

Websitebio-rad.com

Analyst	Recommendation	Action	Price target	Projected	Date
Dan Leonard RBC Capital	Buy	Maintained	$440.00	+20.1%	11/04/2026
Brandon Couillard Wells Fargo	Hold	Reiterated	$330.00	-9.9%	08/05/2026
Daniel Grosslight Citi	Hold	Maintained	$330.00	-9.9%	08/05/2026
Tycho Peterson Jefferies	Hold	Maintained	$275.00	-24.9%	05/21/2026
Unknown Analyst RBC Capital	Buy	Initiated	$320.00	-12.7%	05/14/2026
Patrick B Donnelly Citi	Hold	Downgraded	$300.00	-18.1%	04/07/2026

All values in USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	693.20M	592.10M	651.00M	656.40M
Cost of goods sold	348.40M	282.70M	305.20M	303.10M
Cost of revenue	348.40M	282.70M	305.20M	303.10M
Research and development expenses	66.00M	62.90M	61.20M	60.30M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	217.30M	212.10M	211.80M	215.40M
Operating expense	283.30M	275.00M	273.00M	275.70M
Total operating expenses	631.70M	557.70M	578.20M	578.80M
Operating income	61.50M	34.40M	72.80M	77.60M
Other non operating income	-600.00K	400.00K	600.00K	200.00K
EBT including unusual items	929.20M	-689.80M	542.10M	538.70M
EBT excluding unusual items	81.90M	45.90M	83.80M	77.60M
Income tax expense	209.20M	-162.70M	170.70M	80.10M
Effective tax rate	22.51%	23.59%	31.49%	14.87%
Other operating expenses	-	-	-	-
Net income	720.00M	-527.10M	371.40M	458.60M
Net profit margin	103.87%	-89.02%	57.05%	69.87%
Earnings per share	2.51	1.89	2.62	2.65
Interest and investment income	31.00M	21.00M	22.30M	10.00M
Interest expense	-12.10M	-12.30M	-12.10M	-12.30M
Net interest expenses	18.90M	8.70M	10.20M	-2.30M
Depreciation and amortization charges	-	-	-	-
EBITDA	104.00M	75.30M	113.90M	118.80M
Gain or loss from assets sale	-	-	-	-

Ask anything